Guidant Solution To Panel Dilemma Will Not Require New Contak Implants
This article was originally published in The Gray Sheet
Executive Summary
Guidant's Contak CD "continued access policy" IDE could augment the company's pivotal trial and allow the firm to avoid returning for a second review by the Circulatory System Devices Panel.
You may also be interested in...
COMPANION Results Will Better Define Resynch ICD Population – NEJM
Congestive heart failure patients that are symptomatic due to ischemic cardiomyopathy and a wide QRS complex may be appropriate candidates for resynchronization therapy combined with a defibrillator, an editorial appearing in the June 13 New England Journal of Medicine suggests
COMPANION Results Will Better Define Resynch ICD Population – NEJM
Congestive heart failure patients that are symptomatic due to ischemic cardiomyopathy and a wide QRS complex may be appropriate candidates for resynchronization therapy combined with a defibrillator, an editorial appearing in the June 13 New England Journal of Medicine suggests
Resynchronization Therapy Compromised By ICD Backup, Saxon Tells NASPE
Resynchronization therapy with an implantable defibrillator backup undermines the salutary effect of bi-ventricular pacing for congestive heart failure, according to Leslie Saxon, MD, University of California at San Francisco.[Editors' note: Please see the attached June 6 letter to "The Gray Sheet" from Saxon commenting on the context of her presentation at NASPE. The presentation, Saxon says, should not have been reported literally.]